However, intestinal rehabilitative treatment of SBS patients with the GLP-2 analog teduglutide, which is known to enhance small intestinal absorption as well as morphology with increased both villus length and crypt depth [25,42], is able to decrease parenteral calorie requirements (besides volume requirements as has been shown in numerous studies [24,43,44]). This evidence concerns the gene GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.